PROVECTUS BIOPHARMACEUTICALS, INC.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
PVCT$0.04-17.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Deficit
FOR THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025
(Unaudited)
| Accumulated | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Preferred Stock · Additional · Other · Non- | |||||||||||
| Series D · Series D-1 · Common Stock · Paid-In · Comprehensive · Accumulated · controlling | |||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Interest | Total | |
| Balance at January 1, 2025 | 956,985 | $957 | 13,106,223 | $13,106 | 420,279,879 | $420,280 | $251,090,027 | $(60,741) | $(257,422,961) | $(9,893) | $(5,969,225) |
| Issuance of common stock of majority owned subsidiary | - | - | - | - | - | - | 634,782 | - | - | 65,218 | 700,000 |
| Conversion of 2022 Notes and interest to Series D-1 Preferred Stock | - | - | 365,400 | 365 | - | - | 1,046,329 | - | - | - | 1,046,694 |
| Stock-based compensation: | |||||||||||
| Amortization of stock options | - | - | - | - | - | - | 315,100 | - | - | - | 315,100 |
| Comprehensive loss: | - | ||||||||||
| Net loss | - | - | - | - | - | - | - | - | (1,140,108) | (21,494) | (1,161,602) |
| Other comprehensive income | - | - | - | - | - | - | - | 52 | - | - | 52 |
| Balance at March 31, 2025 | 956,985 | 957 | 13,471,623 | 13,471 | 420,279,879 | 420,280 | 253,086,238 | (60,689) | (258,563,069) | 33,831 | (5,068,981) |
| Conversion of 2022 Notes and interest to Series D-1 Preferred Stock | - | - | 252,940 | 253 | - | - | 723,656 | - | - | - | 723,909 |
| Stock-based compensation: | |||||||||||
| Amortization of stock options | - | - | - | - | - | - | 322,070 | - | - | - | 322,070 |
| Comprehensive loss: | |||||||||||
| Net loss | - | - | - | - | - | - | - | - | (1,814,420) | (37,661) | (1,852,081) |
| Other comprehensive income | - | - | - | - | - | - | - | 328 | - | - | 328 |
| Balance at June 30, 2025 | 956,985 | 957 | 13,724,563 | 13,724 | 420,279,879 | 420,280 | 254,131,964 | (60,361) | (260,377,489) | (3,830) | (5,874,755) |
| Conversion of 2024 Notes and interest to Series D-1 Preferred Stock | - | - | 251,075 | 251 | - | - | 718,314 | - | - | - | 718,565 |
| Stock-based compensation: | |||||||||||
| Amortization of stock options | - | - | - | - | - | - | 312,775 | - | - | - | 312,775 |
| Comprehensive loss: | |||||||||||
| Net loss | - | - | - | - | - | - | - | - | (1,311,281) | (12,348) | (1,323,629) |
| Other comprehensive income | - | - | - | - | - | - | - | 34 | - | - | 34 |
| Balance at September 30, 2025 | 956,985 | $957 | 13,975,638 | $13,975 | 420,279,879 | $420,280 | $255,163,053 | $(60,327) | $(261,688,770) | $(16,178) | $(6,167,010) |
PROVECTUS BIOPHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024
(Unaudited)
| Accumulated | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Preferred Stock · Additional · Other | ||||||||||
| Series D · Series D-1 · Common Stock · Paid-In · Comprehensive · Accumulated | ||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Total | |
| Balance at January 1, 2024 | 12,373,247 | $12,373 | 10,361,097 | $10,361 | 419,522,119 | $419,522 | $244,714,967 | $(60,165) | $(252,690,409) | $(7,593,351) |
| Conversion of 2022 Notes and interest to Series D-1 Preferred Stock | - | - | 226,474 | 226 | - | - | 647,935 | - | - | 648,161 |
| Comprehensive loss: | ||||||||||
| Net loss | - | - | - | - | - | - | - | - | (504,042) | (504,042) |
| Other comprehensive loss | - | - | - | - | - | - | - | (415) | - | (415) |
| Balance at March 31, 2024 | 12,373,247 | 12,373 | 10,587,571 | 10,587 | 419,522,119 | 419,522 | 245,362,902 | (60,580) | (253,194,451) | (7,449,647) |
| Forfeited shares of Series D Preferred Stock | (11,416,262) | (11,416) | - | - | - | - | 11,416 | - | - | - |
| Issuance of Series D-1 Preferred Stock for forfeited shares of Series D Preferred Stock | - | - | 1,141,626 | 1,141 | - | - | (1,141) | - | - | - |
| Conversion of 2022 Notes and interest to Series D-1 Preferred Stock | - | - | 273,691 | 275 | - | - | 783,021 | - | - | 783,296 |
| Comprehensive loss: | - | |||||||||
| Net loss | - | - | - | - | - | - | - | - | (846,848) | (846,848) |
| Other comprehensive income | - | - | - | - | - | - | - | 126 | - | 126 |
| Balance at June 30, 2024 | 956,985 | 957 | 12,002,888 | 12,003 | 419,522,119 | 419,522 | 246,156,198 | (60,454) | (254,041,299) | (7,513,073) |
| Conversion of 2022 Notes and interest to Series D-1 Preferred Stock | - | - | 339,833 | 339 | - | - | 972,261 | - | - | 972,600 |
| Conversion of accrued directors’ fees to Series D-1 Preferred Stock | - | - | 744,878 | 745 | - | - | 2,131,094 | - | - | 2,131,839 |
| Conversion of Series D-1 Preferred Stock to Common Stock | - | - | (75,776) | (75) | 757,760 | 758 | (683) | - | - | - |
| Comprehensive loss: | ||||||||||
| Net loss | - | - | - | - | - | - | - | - | (1,014,351) | (1,014,351) |
| Other comprehensive income | - | - | - | - | - | - | - | 255 | - | 255 |
| Balance at September 30, 2024 | 956,985 | $957 | 13,011,823 | $13,012 | 420,279,879 | $420,280 | $249,258,870 | $(60,199) | $(255,055,650) | $(5,422,730) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.